Off-target effects of BCR–ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia

References

• Deininger M, O'Brien SG, Guilhot F, . International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114(Suppl. 1): Abstract 1126.
   Google Scholar
• Saglio G, Kim DW, Issaragrisil S, . Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362: 2251–2259.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, . Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260–2270.
   PubMed Web of Science ®Google Scholar
• Bantscheff M, Eberhard D, Abraham Y, . Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007;25:1035–1044.
   PubMed Web of Science ®Google Scholar
• Day E, Waters B, Spiegel K, . Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 2008;599:44–53.
   PubMed Web of Science ®Google Scholar
• Karaman MW, Herrgard S, Treiber DK, . A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127–132.
   PubMed Web of Science ®Google Scholar
• Manley PW, Drueckes P, Fendrich G, . Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 2010;1804:445–453.
   PubMed Web of Science ®Google Scholar
• Manley PW, Stiefl N, Cowan-Jacob SW, . Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem 2010;18:6977–6986.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Walters DK, Stoffregen EP, . In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500–4505.
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, . Discovery of N-(2- chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)- 2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658–6661.
   PubMed Web of Science ®Google Scholar
• Hu Y, Liu Y, Pelletier S, . Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004;36:453–461.
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Larson RA, . Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
   PubMed Web of Science ®Google Scholar
• Qiu Z, Cang Y, Goff SP. c-Abl tyrosine kinase regulates cardiac growth and development. Proc Natl Acad Sci USA 2010;107:1136–1141.
   PubMed Web of Science ®Google Scholar
• Hasinoff BB. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicol Appl Pharmacol 2010;244:190–195.
   PubMed Web of Science ®Google Scholar
• Kerkelä R, Grazette L, Yacobi R, . Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908–916.
   PubMed Web of Science ®Google Scholar
• Atallah E, Durand JB, Kantarjian H, . Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007;110:1233–1237.
   PubMed Web of Science ®Google Scholar
• Larson RA, Hochhaus A, Saglio G, . Cardiac safety profile of imatinib and nilotinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): results from ENESTnd. Blood 2010;116(Suppl. 1): Abstract 2291.
   Google Scholar
• Kim TD, le Coutre P, Schwarz M, et al. Clinical cardiac safety profile of nilotinib. Haematologica 2012 Jan 22. [Epub ahead of print]
   Google Scholar
• Aichberger KJ, Herndlhofer S, Schernthaner GH, . Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86:533–539.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol 2011;86:610–611.
   PubMed Web of Science ®Google Scholar
• Le Coutre P, Rea D, Abruzzese E, . Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 2011;103:1347–1348.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Mauro MJ, Hong F, . Retrospective cohort analysis of peripheral arterial occlusive disease (PAOD) events in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP). Blood 2011;118(Suppl. 1): Abstract 2757.
   Google Scholar
• Kantarjian HM, Hochhaus A, Saglio G, . Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12:841–851.
   PubMed Web of Science ®Google Scholar
• Hooi JD, Kester ADM, Stoffers HEJH, . Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am J Epidemiol 2001;153:666–672.
   PubMed Web of Science ®Google Scholar
• Franco C, Hou G, Ahmad PJ, . Discoidin domain receptor 1 (DDR1) deletion decreases atherosclerosis by accelerating matrix accumulation and reducing inflammation in low-density lipoprotein receptor-deficient mice. Circ Res 2008;102:1202–1211.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Kantarjian H, O'Brien S, . Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908–3914.
   PubMed Web of Science ®Google Scholar
• Mattei D, Feola M, Orzan F, . Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009;43:967–968.
   PubMed Web of Science ®Google Scholar
• Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009;33:861–864.
   PubMed Web of Science ®Google Scholar
• Hennigs J, Keller G, Baumann HJ, . Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 2011;11:30.
   PubMedGoogle Scholar
• Tybulewicz VLJ, Crawford CE, Jackson PK, . Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 1991;65:1153–1163.
   PubMed Web of Science ®Google Scholar
• Hantschel O, Rix U, Schmidt U, . The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007;104:13283–13288.
   PubMed Web of Science ®Google Scholar
• Petro JB, Rahman S, Ballard DW, . Bruton's tyrosine kinase is required for activation of IκB kinase and nuclear factor κB in response to B cell receptor engagement. J Exp Med 2000;191:1745–1754.
   PubMed Web of Science ®Google Scholar
• Steegmann JL, Moreno G, Alaez C, . Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica 2003;88:762–768.
   PubMed Web of Science ®Google Scholar
• Valent JN, Schiffer CA. Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib. Leuk Res 2011;35:e1–e3.
   Google Scholar
• Schiffer CA, Cortes JE, Saglio G, . Lymphocytosis following first-line treatment for CML in chronic phase with dasatinib is associated with improved responses: a comparison with imatinib. Blood 2010;116(Suppl. 1): Abstract 358.
   Google Scholar
• Lee SJ, Jung CW, Kim DY, . Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia. Am J Hematol 2011;86:346–350.
   Google Scholar
• Nakasone H, Kanda Y, Takasaki H, . Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia. Leukemia 2010;24:1236–1239.
   PubMed Web of Science ®Google Scholar
• Breccia M, Cannella L, Stefanizzi C, . Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect? Bone Marrow Transplant 2009;44:331–332.
   PubMed Web of Science ®Google Scholar
• Fei F, Yu Y, Schmitt A, . Dasatinib exerts an immunosuppressive effect on CD8 T cells specific for viral and leukemia antigens. Exp Hematol 2008;36:1297–1308.
   PubMed Web of Science ®Google Scholar
• Kreutzman A, Ladell K, Koechel C, . Expansion of highly differentiated CD8 + T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 2011;25:1587–1597.
   PubMed Web of Science ®Google Scholar
• Porkka K, Baccarani M, Hochhaus A, . Occurrence, management, and outcomes in patients with pleural effusion during dasatinib treatment for chronic-phase chronic myeloid leukemia (CML-CP) in the first-line setting: analysis of the DASISION trial. Blood 2010;116(Suppl. 1): Abstract 2282.
   Google Scholar
• Jayson GC, Parker GJ, Mullamitha S, . Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab’, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 2005;23:973–981.
   PubMed Web of Science ®Google Scholar
• Eliceiri BP, Paul R, Schwartzberg PL, . Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999;4:915–924.
   PubMed Web of Science ®Google Scholar
• Mustjoki S, Ekblom M, Arstila TP, . Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398–1405.
   PubMed Web of Science ®Google Scholar
• Porkka K, Khoury HJ, Paquette RL, . Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010;116:377–386.
   PubMed Web of Science ®Google Scholar
• Imatinib prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011.
   Google Scholar
• Mattiuzzi GN, Cortes JE, Talpaz M, . Development of varicella-zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 2003;9:976–980.
   PubMed Web of Science ®Google Scholar
• Breccia M, Girmenia C, Latagliata R, . Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase. Mediterr J Hematol Infect Dis 2011;3:e2011021.
   Google Scholar
• Al-Ameri AM, Cortes JE, Kantarjian H, . Infectious events in patients with chronic myeloid leukemia treated with nilotinib as a front line therapy and after imatinib failure. Blood 2010;116(Suppl. 1): Abstract 1233.
   Google Scholar
• Al-Ameri A, Kantarjian H, Borthakur G, . Opportunistic infections are uncommon with dasatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP). Blood 2009;114(Suppl. 1): Abstract 1120.
   Google Scholar
• Garcia-Munoz R, Galar A, Moreno C, . Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825). Leuk Lymphoma 2007;48:2461–2464.
   PubMed Web of Science ®Google Scholar
• Penel N, Blay JY, Adenis A. Imatinib as a possible cause of severe rhabdomyolysis. N Engl J Med 2008;358:2746–2747.
   PubMed Web of Science ®Google Scholar
• Gordon JK, Magid SK, Maki RG, . Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). Leuk Res 2010;34:827–829.
   PubMed Web of Science ®Google Scholar
• Kim TD, Schwarz M, Nogai H, . Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid 2010;20:1209–1214.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Antolini L, Mahon FX, . Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011;103:553–561.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Tornaghi L, Cavagnini F, . Gynaecomastia in men with chronic myeloid leukaemia after imatinib. Lancet 2003;361:1954–1956.
   PubMed Web of Science ®Google Scholar
• Caocci G, Atzeni S, Orrù N, . Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia. Leukemia 2008;22:2127–2128.
   PubMed Web of Science ®Google Scholar
• Agostino NM, Chinchilli VM, Lynch CJ, . Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract 2011;17:197–202.
   PubMedGoogle Scholar
• Saglio G, Larson RA, Hughes TP, . Efficacy and safety of nilotinib in chronic phase (CP) chronic myeloid leukemia (CML) patients (pts) with type 2 diabetes in the ENESTnd trial. Blood 2010;116(Suppl. 1): Abstract 3430.
   Google Scholar
• Breccia M, Muscaritoli M, Cannella L, . Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res 2008;32:1626–1628.
   PubMed Web of Science ®Google Scholar
• Dingli D, Wolf RC, Vella A. Imatinib and type 2 diabetes. Endocr Pract 2007;13:126–130.
   PubMedGoogle Scholar
• Fitter S, Vandyke K, Schultz CG, . Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab 2010;95:3763–3767.
   PubMed Web of Science ®Google Scholar
• Breccia M, Muscaritoli M, Gentilini F, . Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res 2007;31:1770–1772.
   PubMed Web of Science ®Google Scholar
• Louvet C, Szot GL, Lang J, . Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA 2008;105:18895–18900.
   PubMed Web of Science ®Google Scholar
• Berman E, Nicolaides M, Maki RG, . Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006–2013.
   PubMed Web of Science ®Google Scholar
• Osorio S, Noblejas AG, Duran A, . Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response. Am J Hematol 2007;82:394–395.
   PubMed Web of Science ®Google Scholar
• O'Sullivan S, Naot D, Callon K, . Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 2007;22:1679–1689.
   PubMed Web of Science ®Google Scholar
• Vandyke K, Dewar A, Farrugia A, . Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 2008;23:994–997.
   PubMed Web of Science ®Google Scholar
• Francois H, Coppo P, Hayman JP, . Partial Fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. Am J Kidney Dis 2008;51:298–301.
   PubMed Web of Science ®Google Scholar
• O'Sullivan S, Lin JM, Watson M, . The skeletal effects of the tyrosine kinase inhibitor nilotinib. Bone 2011;49:281–289.
   PubMed Web of Science ®Google Scholar
• Millot F, Baruchel A, Guilhot J, . Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol 2011;29:2827–2832.
   PubMed Web of Science ®Google Scholar
• Vandyke K, Fitter S, Zannettino ACW. The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation. Blood Cancer J 2011;1:e2.
   PubMed Web of Science ®Google Scholar
• Brownlow N, Russell AE, Saravanapavan H, . Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. Leukemia 2007;22:649–652.
   PubMed Web of Science ®Google Scholar
• Marzia M, Sims NA, Voit S, . Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 2000;151:311–320.
   PubMed Web of Science ®Google Scholar
• Berman E, Maki R, Farooki A, . Effects of long term imatinib on bone mineral density in patients with chronic myelogenous leukemia (CML) or gastrointestinal stromal tumor (GIST). Blood 2010;116(Suppl. 1): Abstract 2276.
   Google Scholar
• Ugurel S, Lahaye T, Hildenbrand R, . Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib. Br J Dermatol 2003;149:678–679.
   PubMed Web of Science ®Google Scholar
• Assouline S, Laneuville P, Gambacorti-Passerini C. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med 2006;354:2623–2624.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Shah NP, Cortes JE, . Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119:1123–1129.
   PubMed Web of Science ®Google Scholar
• Valeyrie L, Bastuji-Garin S, Revuz J, . Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003;48:201–206.
   PubMed Web of Science ®Google Scholar
• Arora B, Kumar L, Sharma A, . Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol 2004;15:358–359.
   PubMed Web of Science ®Google Scholar
• Watabe H, Soma Y, Kawa Y, . Differentiation of murine melanocyte precursors induced by 1,25-dihydroxyvitamin D3 is associated with the stimulation of endothelin B receptor expression. J Invest Dermatol 2002;119:583–589.
   PubMed Web of Science ®Google Scholar
• Kimura S, Kawakami T, Kawa Y, . Bcl-2 reduced and fas activated by the inhibition of stem cell factor/KIT signaling in murine melanocyte precursors. J Invest Dermatol 2004;124:229–234.
   Web of Science ®Google Scholar
• Abram CL, Courtneidge SA. Src family tyrosine kinases and growth factor signaling. Exp Cell Res 2000;254:1–13.
   PubMed Web of Science ®Google Scholar
• Cross TJ, Bagot C, Portmann B, . Imatinib mesylate as a cause of acute liver failure. Am J Hematol 2006;81:189–192.
   PubMed Web of Science ®Google Scholar
• Dasatinib prescribing information. Princeton, NJ: Bristol-Myers Squibb Co.; 2011.
   Google Scholar
• Deininger MW, O'Brien SG, Ford JM, . Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637–1647.
   PubMed Web of Science ®Google Scholar
• Ohyashiki K, Kuriyama Y, Nakajima A, . Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 2002;16: 2160–2161.
   PubMed Web of Science ®Google Scholar
• Ferrero D, Pogliani EM, Rege-Cambrin G, . Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica 2006;91(6 Suppl.):ECR27.
   Google Scholar
• Cortes JE, Jones D, O'Brien S, . Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010;28:398–404.
   PubMed Web of Science ®Google Scholar
• Bonvin A, Mesnil A, Nicolini F, . Dasatinib-induced acute hepatitis. Leuk Lymphoma 2008;49:1630–1632.
   PubMed Web of Science ®Google Scholar
• Singer JB, Shou Y, Giles F, . UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 2007;21:2311–2315.
   PubMed Web of Science ®Google Scholar
• Yin OQ, Gallagher N, Tanaka C, . Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. Clin Ther 2009;31:2459–2469.
   PubMed Web of Science ®Google Scholar
• Quint s-Cardama A, Kantarjian H, Ravandi F, . Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 2009;115:2482–2490.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Han X, Kantarjian H, . Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114:261–263.
   PubMed Web of Science ®Google Scholar
• Gratacap MP, Martin V, Valera MC, . The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 2009;114:1884–1892.
   PubMed Web of Science ®Google Scholar
• Mazharian A, Ghevaert C, Zhang L, . Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation. Blood 2011;117:5198–5206.
   PubMed Web of Science ®Google Scholar
• Mogalluru SU. Effect of imatinib mesylate on platelet aggregation abnormalities in BCR-ABL + CML patients. Haematologica 2009;94 (Suppl. 2): Abstract 1463.
   Google Scholar
• Gugliotta G, Castagnetti F, Palandri F, . Second malignancies in 559 patients with chronic myeloid leukemia treated with imatinib frontline: data from the GIMEMA CML Working Party. Haematologica 2010;95(Suppl. 2): Abstract 0805.
   Google Scholar
• Verma D, Kantarjian H, Strom SS, . Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 2011;118:4353–4358.
   PubMed Web of Science ®Google Scholar
• Luciano L, Cerchione C, Ciancia R, . Renal failure associated to tyrosine kinase inhibitors. Haematologica 2010;95(Suppl. 2): Abstract 1330.
   Google Scholar
• Marcolino MS, Boersma E, Clementino NC, . Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol 2011;22:2073–2079.
   PubMed Web of Science ®Google Scholar
• Ozkurt S, Temiz G, Acikalin MF, . Acute renal failure under dasatinib therapy. Ren Fail 2010;32:147–149.
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Kelly DJ, Mckay T, . PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 2001;59:1324–1332.
   PubMed Web of Science ®Google Scholar
• Tong WG, Kantarjian H, O'Brien S, . Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Cancer 2010;116:3152–3159.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Levy V, . Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115: 4136–4147.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Cortes JE, Kim D, . Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up. J Clin Oncol 2011;29(Suppl.): Abstract 6509.
   Google Scholar
• White D, Saunders V, Lyons AB, . In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005;106: 2520–2526.
   PubMed Web of Science ®Google Scholar
• Quint s-Cardama A, Tong W, Manshouri T, . Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia 2008;22:1117–1124.
   PubMed Web of Science ®Google Scholar
• De Braekeleer E, Douet-Guilbert N, Rowe D, . ABL1 fusion genes in hematological malignancies: a review. Eur J Haematol 2011;86:361–371.
   PubMed Web of Science ®Google Scholar
• Nand R, Bryke C, Kroft SH, . Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. Leuk Res 2009;33: 1144–1146.
   PubMed Web of Science ®Google Scholar
• Stover EH, Chen J, Lee BH, . The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo. Blood 2005;106:3206–3213.
   PubMed Web of Science ®Google Scholar